Literature DB >> 28451532

Screening of Myo7A Mutations in Iranian Patients with Autosomal Recessive Hearing Loss from West of Iran.

Samira Asgharzade1,2, Somayeh Reiisi3, Mohammad Amin Tabatabaiefar4, Morteza Hashemzadeh Chaleshtori2.   

Abstract

BACKGROUND: Hearing loss (HL) is the most frequent neurosensory impairment. HL is highly heterogeneous defect. This disorder affects 1 out of 500 newborns. This study aimed to determine the role of DFNB2 locus and frequency of MYO7A gene mutations in a population from west of Iran.
METHODS: Thirty families investigated in Shahrekord University of Medical Sciences in 2014, genetic linkage analysis via four short tandem repeat markers linked to MYO7A was performed for two consanguineous families originating from Hamedan (family-13) and Chaharmahal-Bakhtiari (family-32) provinces of Iran, co-segregating autosomal recessive HL and showed no mutation in GJB2 gene in our preliminary investigation. All 49 coding exons and exon- intron boundaries of the MYO7A gene were amplified by PCR and analyzed using direct DNA sequencing.
RESULTS: Two of families displayed linkage to DFNB2. Family-13 segregated a homozygous missense mutation (c.6487G>A) in exon 48 that results in a p.G2163S amino acid substitution in C-terminal domain of the myosin VIIA protein. While family-32 segregated a homozygous nonsense mutation (c.448 C>T) in exon five, resulting in a premature truncation at amino acid position 150 (p.Arg150X) in the motor domain of this protein.
CONCLUSION: Mutation frequency of MYO7A gene in different populations of Iran as well as cause of HL in most cases are still unknown and more extensive studies have to be done.

Entities:  

Keywords:  DFNB2; Deafness; Iran; Linkage analysis; MYO7A

Year:  2017        PMID: 28451532      PMCID: PMC5401939     

Source DB:  PubMed          Journal:  Iran J Public Health        ISSN: 2251-6085            Impact factor:   1.429


Introduction

Hereditary non-syndromic hearing loss (HL) is the most common defect that attributed to both genetical and environmental factors and has an incidence of 1 in 500 infants (1). HL is extremely heterogeneous defect and up to date, about 62 genes have been identified for autosomal recessive non-syndromic hearing loss (ARNSHL) (2). More than thousands mutations in more than 60 genes have been identified which associate with HL (2), however, most of HL causes and their mutation is still unknown. One group of genes associated with HL is Myosin. Myosins are a superfamily consisting of more than 35 classes and they are actin-based molecular motors (3). N-terminal region of myosin heavy chain consists of highly conserved sequences and its head domain following a divergent neck domain. N-terminal region of head domain binds to actin and ATP (4). C-terminal region of Myosin is known as tail domain and in various classes of Myosin is highly divergent. Myosins are mainly classified to conventional and unconventional (5). Myosin VIIA (MYO7A) belongs to unconventional myosins, has 49 exons, and mostly is expressed in inner ear and retina (6). MYO7A is made in inner eye and contribute to organization of the stereocilia in the hair bundles. Up to now, 340 different mutations and more than 248 protein variants in MYO7A associated with these disorders have been reported (7) (http://www.umd.be-/MYO7A/) that affect the head and tail domains (7). Defects in MYO7A are cause of syndromic (USH1B) and nonsyndromic deafness (two form of dominant (DFNA11) and recessive (DFNB2) deafness) (7, 8). Mutations in the head domain are thought to affect MYO7A motor function, but there is little known about the affect protein function when mutations in the tail domain (8). This present study aimed to determine mutation frequency in MYO7A and linkage analysis of DFNB2 locus.

Materials and Methods

Subjects and Sampling

The Institutional Review Boards of Tehran University of Medical Sciences and Shahrekord University of Medical Sciences approved this descriptive laboratory study in 2014. Thirty families (405 individual) including 158 affected individuals of clients of state welfare organization and exceptional children education organization from Hamedan and Kohgiluyeh and Boyer-Ahmad provinces in the west of Iran were included in this study. Families investigated had at least two affected children. Parents were unaffected and majority of them had consanguineous marriages. All patients underwent audiogram hearing test and ear, nose and throat (ENT) specialist confirmed presence of HL in patients. All families were informed and written consent was obtained. Then 5 cc peripheral blood in tubes containing 0.5 M EDTA from all available members of all families were captured.

DNA extraction

Genomic DNA was extracted from blood samples using phenol-chloroform standard method (9). DNA quality (UNICO 2100, USA) and on 0.5% agarose gel stained with 0.5 x gel red (10).

STR (Short tandem repeats) marker genotyping and linkage analysis

For analyzing of locus, four different STR markers were used. Upon encountering an uninformative marker, further markers were examined. In Table 1, used markers and their characteristics are shown.
Table 1:

STR marker used in study and their characteristics

STR marker Physical position HZ (%) Amplicon Size Forward Primer Reverse Primer
D11S417976,396,260 –76,396,49572200–256GGATGTAAGAGTAACTGGCTCCGGAAAATGTTCTGCCTGAGGG
D11S418676,968,518 –76,968,68579154–175ATTCTCCCAATCTATCGCTCGGGCAGTAATGATGATGTG
D11S407977,119,447 –77,119,70175217–265CAGCAAGATCCTGTCTCAACTCCTTAAAGTGGGGGAGTT
D11S91177,448,583 – 77,448,76985159–203CTTCTCATGCTTGACCATTTCTTCTGAACAATTGCCACAT

HZ: Heterozygous

STR marker used in study and their characteristics HZ: Heterozygous The criteria for selecting these markers are as following greater heterozygosity values, shorter fragments in length and lying close to the known locus. For S-Link and LOD score calculation, we used genetic software Easy linkage plus ver. 5.05 (11). For S-Link calculation, we used Fast Slink ver. 2.51. Two-point and multipoint parametric LOD scores were calculated by Super link ver. 1.6, Gene hunter ver. 2.91, respectively. For LOD score calculations using this software, inheritance pattern of autosomal recessive, complete penetrance and disease allele frequency of 0.001 were assumed. Haplopainter ver. 029.5 software was used for reconstruction of haplotypes (12). Negative subjects for connexin 26 gene mutation are selected for linkage analysis. STR markers were selected based on their physical distance found at NCBI Uni STS. For markers Primers, NCBI Map Viewer is used and Touchdown program is used for markers.

Mutation screening of MYO7A

In order to analyze the mutation in families linked to mentioned locus, for 49 exons, intronexon boundaries, primers were designed by Oligo ver. 6.7.1.0 (National Biosciences Inc., Plymouth, MN, USA) and Primer3 software (https://www.genome.com/cgi-bin/primer/primer3_www.cgi). Thermal cycling conditions for amplifying exons were as follows: 95 °C for primary denaturation for 5 min, 8 touchdown cycles of 94 °C denaturation of DNA strands for 30 sec, 55 °C to 62 °C annealing temperature for 30 sec, 72 °C extension for 30 sec and in next 25 cycles of 94 °C denaturation for 30 sec, 54 °C annealing temperature for 30 sec, 72 °C extension for 30 sec and 72 °C final extension for 5 min. In each PCR, 0.5 μl of each primers (10 PM), 0.5 μl dNTP mix (10 mM), 1 μl MgCl2 (50 mM), 0.1 μl Taq polymerase (5 unit/μl), 2 μl genomic DNA (50 ng). The total volume was adjusted to 25 μl by ddH2O. After amplifying desired piece of DNA, PCR product for each family separately was run in 8–12% polyacrylamide gel electrophoresis at 35–40 mA for 3 h, following silver staining of the gel, bands were visualized. DNA sequencing of the PCR- products was performed bi-directionally on an ABI 3730XL automated sequencer (Applied Bio-systems, Macrogen and, Seoul, Korea) than any variant in this gene sequence using Seqmqn software analyzer and Chromas software http://www.technelysium.com.au/chromas.html were detected.

Results

Majority of studied subjects showed severe to profound bilateral neurosensory HL. Seventy percent of investigated families in present study were consanguineous families. Based on information given in pedigree, type of HL was autosomal recessive. Among the investigated families, two families displayed linkage to DNFB2 locus and by analysis of MYO7A gene two mutations have been detected. Estimated maximum Slink for these 30 families ranged from 1.12 to 7.68, two-point and multipoint LOD and S-link scores related to two families are indicated in Table 2.
Table 2:

S-Link and LOD scores calculated for family linked to DFNB3

FamilyS-LINKTwo point LOD scoreMultipoint LOD score
Family- 132.531.962.30
Family -322.533.21.3
S-Link and LOD scores calculated for family linked to DFNB3 Family-13: This family was from Hamedan province (Fig. 1) and after sequencing of MYO7A gene, homozygous missense mutation c.6487 G>A was found in exon 48 that result in an amino acid substitution (p.G2163S) in C-terminal FERM (F for 4.1 protein, E for ezrin, R for radixin and M for moesin) domain of the myosin VIIA protein (Fig. 2). This Mutation in parents and non-affected children was in heterozygous state and parents had consanguineous marriage. Onset of hearing loss was prelingual and the progress of HL was unchanged, audiogram-hearing test confirmed the type of severe to profound.
Fig. 1:

pedigree and Haplotype of Family-13

Fig. 2:

Chromatograms results of MYO7A mutation in Family-13. A: normal alleles for c.6487 G>A. B: mutant allele of c.6487 G>A.

pedigree and Haplotype of Family-13 Chromatograms results of MYO7A mutation in Family-13. A: normal alleles for c.6487 G>A. B: mutant allele of c.6487 G>A. Family-32: This family was from Kohgiluyeh and Boyer-Ahmad province and consanguineous marriage was three grade (Fig. 3).
Fig. 3:

Pedigree and Haplotype of Family-32

Pedigree and Haplotype of Family-32 Affected individuals in this family showed profound hearing loss along with progressive retinitis pigmentosa and vestibular dysfunction. Mentioned clinical signs and symptoms may suggest presence of USHB1. By sequencing of MYO7A gene, homozygous nonsense mutation (c.448 C>T) in exon five was detected (Fig. 4) that resulting in a premature truncation at amino acid position 150 (p.Arg150X) in the motor domain of this protein.
Fig. 4:

Chromatograms results of MYO7A mutation in Family-32. A: normal alleles for c.448 C>T. B: mutant allele of c.448 C>T.

Chromatograms results of MYO7A mutation in Family-32. A: normal alleles for c.448 C>T. B: mutant allele of c.448 C>T.

Discussion

In this study, 30 families with at least two affected subjects from provinces of Hamedan and Kohgiluyeh and Boyer-Ahmad were investigated. Linkage analysis and haplotype analysis of STR molecular markers in DFNB2 locus for families with no mutation in connexin 26 were carried out. Since mutation in connexin 26 is responsible for 18.29% of hearing loss in consanguineous families (13) and hearing loss is highly heterogeneous and due to presence of different ethnic groups (14) and high rate of consanguineous marriages in Iran, analysis of other loci associated with hearing loss in different populations of Iran is necessary (15–17). Thus, by analysis of families with no mutation in connexin 26 and other genes associated with HL. We can gain new insight into frequency of these genes. In this investigation, two families were found to be linked to DFNB2 locus. After sequencing of MYO7A gene, 2 variants c.448C>T in Motor domain and c.6487 G>A in the C-terminal FERM2 domain of MYO7A have been identified. MYO7A gene (NM_000260.3) is consisting of 49 exons that encode a protein with 2215 amino acids. Up to date, majority of mutations identified in MYO7A were associated with ARNSHL and Usher syndrome and few number of these mutations were associated with ADNSHL (DFNB11) (6). These mutations mostly cause loss of protein function. DFNB2 locus in one Tunisian family with non-syndromic hearing loss was mapped (18), and up to date mutations in MYO7A in patients with hearing loss from different populations such as China (19), Tunisia (20), Pakistan (21), Taiwan (22) and Iran have been reported (23). One of identified mutations in this study is c.448C>T which is nonsense and changes argi-nine amino acid in protein at position 150 for stop codon (p.Arg150X), this mutation occurs in motor domain of Myosin VII protein. The motor domain contains actin- binding domain and thought to be involved in mechanical movement of hair bundles using ATP, mutation in this protein binding site results in loss of function of actin protein and as a result, action cannot bind to the site and consequently cannot have normal movements. This mutation was first reported in patients with Usher syndrome that caused an abnormal protein near ATP binding site (24, 25). Based on clinical examination of patients, this study may suggest the presence of Usher syndrome type I. Mutation c.6487 G>A converts glycine amino acid to serine at position 2163 (Gly2163Ser). This mutation occurs in C-terminal FERM2 domain of protein interacts with specific proteins and confers specificity to Myosin VIIA and mutations in this domain results in protein instability and impairment in binding of other proteins to tail domain. This mutation was first in one Palestinian family and then later in one Iranian family was reported (21, 26). After sequencing of MYO7A gene, this mutation was attributed to cause of hearing loss in family-13. Mutation frequency of MYO7A gene in different populations of Iran as well as cause of hearing loss in most cases are still unknown and more extensive studies have to be done.

Conclusion

The mutation analysis of MYO7A gene led to the identification of two mutations in two families including missense mutations in different regions of the myosin-XV protein. MYO7A mutational frequency displayed of 6.67% in our cohort of deaf Iranian families.

Ethical considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.
  22 in total

1.  easyLINKAGE: a PERL script for easy and automated two-/multi-point linkage analyses.

Authors:  Tom H Lindner; K Hoffmann
Journal:  Bioinformatics       Date:  2004-09-03       Impact factor: 6.937

2.  Mutations in the myosin VIIA gene cause non-syndromic recessive deafness.

Authors:  X Z Liu; J Walsh; P Mburu; J Kendrick-Jones; M J Cope; K P Steel; S D Brown
Journal:  Nat Genet       Date:  1997-06       Impact factor: 38.330

3.  A novel TECTA mutation causes ARNSHL.

Authors:  Samira Asgharzade; Mohammad Amin Tabatabaiefar; Mohammad Hossein Modarressi; Mohammad Hossein Ghahremani; Somayeh Reiisi; Parisa Tahmasebi; Fatemeh Abdollahnejad; Morteza Hashemzadeh Chaleshtori
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2016-11-15       Impact factor: 1.675

4.  Novel compound heterozygous mutations in MYO7A gene associated with autosomal recessive sensorineural hearing loss in a Chinese family.

Authors:  Yalin Ma; Yun Xiao; Fengguo Zhang; Yuechen Han; Jianfeng Li; Lei Xu; Xiaohui Bai; Haibo Wang
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2016-01-07       Impact factor: 1.675

5.  Identification of novel variants in the Myosin VIIA gene of patients with nonsyndromic hearing loss from Taiwan.

Authors:  Mao-Chang Su; Jiann-Jou Yang; Ching-Chyuan Su; Chung-Han Hsin; Shuan-Yow Li
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2009-03-18       Impact factor: 1.675

6.  Novel myosin mutations for hereditary hearing loss revealed by targeted genomic capture and massively parallel sequencing.

Authors:  Zippora Brownstein; Amal Abu-Rayyan; Daphne Karfunkel-Doron; Serena Sirigu; Bella Davidov; Mordechai Shohat; Moshe Frydman; Anne Houdusse; Moien Kanaan; Karen B Avraham
Journal:  Eur J Hum Genet       Date:  2013-10-09       Impact factor: 4.246

7.  Characterising the spectrum of autosomal recessive hereditary hearing loss in Iran.

Authors:  Christina M Sloan-Heggen; Mojgan Babanejad; Maryam Beheshtian; Allen C Simpson; Kevin T Booth; Fariba Ardalani; Kathy L Frees; Marzieh Mohseni; Reza Mozafari; Zohreh Mehrjoo; Leila Jamali; Saeideh Vaziri; Tara Akhtarkhavari; Niloofar Bazazzadegan; Nooshin Nikzat; Sanaz Arzhangi; Farahnaz Sabbagh; Hasan Otukesh; Seyed Morteza Seifati; Hossein Khodaei; Maryam Taghdiri; Nicole C Meyer; Ahmad Daneshi; Mohammad Farhadi; Kimia Kahrizi; Richard J H Smith; Hela Azaiez; Hossein Najmabadi
Journal:  J Med Genet       Date:  2015-10-07       Impact factor: 6.318

8.  Expression in cochlea and retina of myosin VIIa, the gene product defective in Usher syndrome type 1B.

Authors:  T Hasson; M B Heintzelman; J Santos-Sacchi; D P Corey; M S Mooseker
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

9.  Genetic Linkage Analysis of 15 DFNB Loci in a Group of Iranian Families with Autosomal Recessive Hearing Loss.

Authors:  Ma Tabatabaiefar; F Alasti; M Montazer Zohour; L Shariati; E Farrokhi; Dd Farhud; Gv Camp; Mr Noori-Daloii; M Hashemzadeh Chaleshtori
Journal:  Iran J Public Health       Date:  2011-06-30       Impact factor: 1.429

10.  Drawing the tree of eukaryotic life based on the analysis of 2,269 manually annotated myosins from 328 species.

Authors:  Florian Odronitz; Martin Kollmar
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  2 in total

1.  Spectrum of MYO7A Mutations in an Indigenous South African Population Further Elucidates the Nonsyndromic Autosomal Recessive Phenotype of DFNB2 to Include Both Homozygous and Compound Heterozygous Mutations.

Authors:  Rosemary Ida Kabahuma; Wolf-Dieter Schubert; Christiaan Labuschagne; Denise Yan; Susan Halloran Blanton; Michael Sean Pepper; Xue Zhong Liu
Journal:  Genes (Basel)       Date:  2021-02-15       Impact factor: 4.096

2.  The first case of NSHL by direct impression on EYA1 gene and identification of one novel mutation in MYO7A in the Iranian families.

Authors:  Ehsan Razmara; Fatemeh Bitarafan; Elika Esmaeilzadeh-Gharehdaghi; Navid Almadani; Masoud Garshasbi
Journal:  Iran J Basic Med Sci       Date:  2018-03       Impact factor: 2.699

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.